Click here for slides on this topic


EXAMINE

Cardiovascular safety study of the DPP-4 inhibitor, alogliptin. EXAMINE is an acronym for EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome.
The following content matched the glossary term: EXAMINE

No Increased Risk of Pancreatic Cancer With Incretins

Top

Data presented at EASD 2015 show no causal association between the use of incretin based therapies—DPP-4 inhibitors and GLP-1 receptor agonists—and pancreatitis or pancreatic cancer

NDEI.org Expert Commentary Ed Horton, MD, on EMPA-REG OUTCOME Results

Top

Ed Horton, MD, discusses EMPA-REG OUTCOME results: SGLT2 inhibitor, empagliflozin, cuts CV deaths in high-risk type 2 diabetes patients

NDEI.org Expert Commentary Vivian Fonseca, MD, on EMPA-REG OUTCOME: Empagliflozin Cuts CV Deaths

Top

Vivian Fonseca, MD, discusses the impact of EMPA-REG OUTCOME; SGLT2 inhibitor, empagliflozin, reduced cardiovascular deaths in high-risk type 2 diabetes patients

Empagliflozin Cuts Cardiovascular Deaths in Landmark Trial

Top

The SGLT2 inhibitor, empagliflozin, reduces cardiovascular deaths in the EMPA-REG OUTCOME trial. Includes expert commentary.

No Heart Failure Risk With DPP-4 Inhibitor, Sitagliptin, in TECOS Subanalysis

Top

Data from a subanalysis of TECOS at ESC Congress 2015 confirms that the DPP-4 inhibitor, sitagliptin, does not cause heart failure in patients with type 2 diabetes. Includes expert commentary.

NDEI.org Expert Commentary Silvio Inzucchi MD on TECOS Subanalysis No Heart Failure Risk With Sitagliptin in High-Risk Type 2 Diabetes

Top

Silvio Inzucchi, MD, provides expert commentary on data from a subanalysis of TECOS, which confirmed that the DPP-4 inhibitor, sitagliptin, does not cause heart failure in patients with type 2 diabetes; from ESC Congress 2015.

NDEI.org Expert Commentary Vivian Fonseca MD on Results of ELIXA the First Cardiovascular Safety Study to Report Outcomes With A GLP-1 Receptor Agonist

Top

In this diabetes expert blog, Vivian Fonseca, MD, provides insights on results of the ELIXA cardiovascular safety study of the novel (at time of publishing) GLP-1 receptor agonist, lixisenatide.

ADA 2015: The 75th Scientific Sessions of the American Diabetes Association

Top

Coverage of data from ADA 2015, June 5-9, 2015 in Boston, Massachusetts



Slide Library Results

Search Results for: EXAMINE Slides Found: 32
Obesity Predicts Depression: Prospective Data
Diabetes Is a Risk Factor for PAD and Its Associated Mortality
Vildagliptin Monotherapy Improves Glycemic Control in Type 2 Diabetes
UKPDS: Intensive SU-Insulin vs Conventional Therapy: Any Diabetes Endpoint
UKPDS: Intensive Metformin vs Conventional Therapy: Diabetes Endpoints
UKPDS: Intensive SU-Insulin vs Conventional Therapy: Myocardial Infarction
UKPDS: Intensive Metformin vs Conventional Therapy: Myocardial Infarction
UKPDS: Intensive SU-Insulin vs Conventional Therapy: Death From Any Cause
UKPDS: Intensive Metformin vs Conventional Therapy: Death From Any Cause
Risk of CVD Mortality Risk rate Among Men with MetSyn and Diabetes, Alone and in Combination
Hazard Ratios of CVD Mortality Among Men With MetSyn and Diabetes, Alone and in Combination
BP and Type 2 Diabetes Risk in African Americans and Whites: Design
BP and Type 2 Diabetes Risk in African Americans and Whites: Results
STAMPEDE: Design
ORIGIN: Design
JUPITER: Study Design
JUPITER Results: Primary Endpoint
JUPITER Results: Components of Primary Endpoint
JUPITER Results: Summary
Roux-en-Y Gastric Bypass Surgery in Type 2 Diabetes and Mild Obesity: Design
Can Coronary Artery Calcium Predict CVD Outcomes in Type 2 Diabetes?
EXAMINE: No Increase in CV Events with Alogliptin Primary Endpoint
EXAMINE: No Increase in CV Events with Alogliptin Secondary Endpoint
EXAMINE: Significantly Greater A1C Change from Baseline with Alogliptin Vs Placebo
EXAMINE: Adverse Events
EXAMINE: Design
Risk of Acute Pancreatitis Rare in Incretin-Treated Type 2 Diabetes | NDEI
Incretins Therapies & Heart Failure Risk in Type 2 Diabetes PPT | NDEI
No Increased Acute Pancreatitis Risk With Incretins Type 2 Diabetes | NDEI
TECOS Heart Failure Sitaliptin DPP-4 CV Safety | NDEI
Relationship Between DPP-4 Inhibitors & Heart Failure Diabetes | NDEI
Effect of DPP-4 Inhibitors Vs Placebo on Heart Failure in Diabetes | NDEI